ATE465162T1 - Tricyclische verbindungen auf 1,6-dihydro-1,3,5,6-tetraaza-as-indacen-basis und diese enthaltende pharmazeutische zusammensetzungen als inhibitoren der ikk-enzymaktivität - Google Patents

Tricyclische verbindungen auf 1,6-dihydro-1,3,5,6-tetraaza-as-indacen-basis und diese enthaltende pharmazeutische zusammensetzungen als inhibitoren der ikk-enzymaktivität

Info

Publication number
ATE465162T1
ATE465162T1 AT06759417T AT06759417T ATE465162T1 AT E465162 T1 ATE465162 T1 AT E465162T1 AT 06759417 T AT06759417 T AT 06759417T AT 06759417 T AT06759417 T AT 06759417T AT E465162 T1 ATE465162 T1 AT E465162T1
Authority
AT
Austria
Prior art keywords
tetraaza
indacene
ikk
dihydro
inhibitors
Prior art date
Application number
AT06759417T
Other languages
German (de)
English (en)
Inventor
William J Pitts
James Kempson
Junqing Guo
Jagabandhu Das
Charles M Langevine
Steven H Spergel
Scott H Watterson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE465162T1 publication Critical patent/ATE465162T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06759417T 2005-05-10 2006-05-09 Tricyclische verbindungen auf 1,6-dihydro-1,3,5,6-tetraaza-as-indacen-basis und diese enthaltende pharmazeutische zusammensetzungen als inhibitoren der ikk-enzymaktivität ATE465162T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67969205P 2005-05-10 2005-05-10
US11/430,215 US7737279B2 (en) 2005-05-10 2006-05-08 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
PCT/US2006/017950 WO2006122137A1 (en) 2005-05-10 2006-05-09 1, 6 -dihydro- 1,3, 5, 6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same as inhibitors of ikk enzyme activity

Publications (1)

Publication Number Publication Date
ATE465162T1 true ATE465162T1 (de) 2010-05-15

Family

ID=36808856

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759417T ATE465162T1 (de) 2005-05-10 2006-05-09 Tricyclische verbindungen auf 1,6-dihydro-1,3,5,6-tetraaza-as-indacen-basis und diese enthaltende pharmazeutische zusammensetzungen als inhibitoren der ikk-enzymaktivität

Country Status (15)

Country Link
US (2) US7737279B2 (enExample)
EP (1) EP1888584B1 (enExample)
JP (1) JP5047164B2 (enExample)
AR (1) AR053725A1 (enExample)
AT (1) ATE465162T1 (enExample)
CY (1) CY1110419T1 (enExample)
DE (1) DE602006013816D1 (enExample)
DK (1) DK1888584T3 (enExample)
ES (1) ES2342976T3 (enExample)
PE (1) PE20061424A1 (enExample)
PL (1) PL1888584T3 (enExample)
PT (1) PT1888584E (enExample)
SI (1) SI1888584T1 (enExample)
TW (1) TW200718422A (enExample)
WO (1) WO2006122137A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737279B2 (en) * 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
UY31881A (es) 2008-06-10 2010-01-29 Abbott Lab Derivados sustituidos de imidazo[1,5-a]pirrolo[2,3-e]pirazinas e imidazo[1,2-a]pirrolo[2,3-e]pirazinas, sus sales, prodrogas, metabolitos biológicalmente activos, estereoisómeros e isómeros farmacéuticamente aceptables.
AU2010289497B2 (en) 2009-09-03 2016-04-14 Bristol-Myers Squibb Company JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
CA2991896A1 (en) * 2009-12-01 2011-06-09 Abbvie Inc. Novel tricyclic compounds as protein kinase inhibitors
KR20120102724A (ko) 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
CN102712640A (zh) * 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
WO2011112687A2 (en) * 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
RS59512B1 (sr) * 2012-09-25 2019-12-31 Hoffmann La Roche Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9518058B2 (en) 2013-08-29 2016-12-13 Bristol-Myers Squibb Company Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
JPWO2015060368A1 (ja) 2013-10-23 2017-03-09 武田薬品工業株式会社 複素環化合物
WO2015078803A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
KR20160128428A (ko) 2014-03-26 2016-11-07 에프. 호프만-라 로슈 아게 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
EP3353178B1 (en) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
KR20180054635A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서 이환형 화합물
PE20180461A1 (es) 2015-09-24 2018-03-06 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de la atx
CR20180143A (es) 2015-09-24 2018-05-03 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
SG10201913989QA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN109843294A (zh) * 2016-08-15 2019-06-04 普渡研究基金会 4-取代的氨基异喹啉衍生物
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
DK3555097T3 (da) 2016-12-16 2022-07-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2022074572A1 (en) * 2020-10-08 2022-04-14 Unichem Laboratories Ltd Substituted tricyclic compounds
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418179A3 (en) 1990-01-11 2006-03-08 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating rna activity and gene expression
EP1060181B1 (en) 1998-02-26 2004-05-06 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases
TWI271406B (en) * 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CA2420967A1 (en) 2000-08-07 2002-02-14 Neurogen Corporation Heterocyclic compounds as ligands of the gabaa receptor
EP1490371B1 (en) * 2002-04-03 2007-08-15 Bristol-Myers Squibb Company Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
US7329668B2 (en) * 2003-02-25 2008-02-12 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7071333B2 (en) * 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
PL1653959T3 (pl) * 2003-08-14 2015-10-30 3M Innovative Properties Co Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
US20050250829A1 (en) 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
WO2006053166A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7456194B2 (en) * 2004-11-12 2008-11-25 Bristol-Myers Squibb Company Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7737279B2 (en) * 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
JP2008540547A (ja) 2008-11-20
JP5047164B2 (ja) 2012-10-10
DE602006013816D1 (de) 2010-06-02
PT1888584E (pt) 2010-06-22
US20060270654A1 (en) 2006-11-30
US8268855B2 (en) 2012-09-18
WO2006122137A1 (en) 2006-11-16
PL1888584T3 (pl) 2010-09-30
US7737279B2 (en) 2010-06-15
US20100210629A1 (en) 2010-08-19
ES2342976T3 (es) 2010-07-20
EP1888584A1 (en) 2008-02-20
SI1888584T1 (sl) 2010-07-30
TW200718422A (en) 2007-05-16
EP1888584B1 (en) 2010-04-21
PE20061424A1 (es) 2006-12-17
DK1888584T3 (da) 2010-08-09
AR053725A1 (es) 2007-05-16
CY1110419T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
ATE465162T1 (de) Tricyclische verbindungen auf 1,6-dihydro-1,3,5,6-tetraaza-as-indacen-basis und diese enthaltende pharmazeutische zusammensetzungen als inhibitoren der ikk-enzymaktivität
ATE542799T1 (de) Chinolinonderivate als parp und tank-inhibitoren
DE602006021169D1 (de) Spiroheterocyclische verbindungen und ihre anwendungen als therapeutische mittel
ATE467413T1 (de) Oxindolderivate als antikrebsmittel
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
EA200800240A1 (ru) Производные тиазола в качестве активатора амфк
ECSP12011961A (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de
EA201070169A1 (ru) 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы
ATE369372T1 (de) 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
ATE473975T1 (de) Chemische verbindungen
ATE517621T1 (de) Verwendung von ampk-aktivierenden imidazol- derivaten, herstellungsverfahren dafür und diese enthaltende pharmazeutische zusammensetzungen
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
EP1962827A4 (en) PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4-INHIBITORS WITH METFORMIN
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
SV2007002007A (es) Compuestos de quinolina sustituidos ref. pc 25932a
ATE502951T1 (de) Verbindungen und zusammensetzungen als kanalaktivierende protease-hemmer
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
EP2089354A4 (en) NAPHTHALINYL OXYPROPENYL DERIVATIVES WITH HEMMOTHER EFFECT ON HISTONDEACETYLASE, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
NO20085317L (no) Imidazoazepinonforbindelser
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
ATE534626T1 (de) Piperazinamidine als antivirale mittel
BRPI0616111B8 (pt) derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto
CY1111899T1 (el) Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1888584

Country of ref document: EP